Abstract
Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Keywords: Acute coronary syndrome, angioplasty, clopidogrel, myocardial infarction, prasugrel, stent, thienopyridine, stroke, transient ischemic attack, thrombolysis
Current Vascular Pharmacology
Title:Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data
Volume: 10 Issue: 4
Author(s): Giuseppe Biondi-Zoccai, Antonio Abbate, Fabrizio D’Ascenzo, Marzia Lotrionte and Maria G. Modena
Affiliation:
Keywords: Acute coronary syndrome, angioplasty, clopidogrel, myocardial infarction, prasugrel, stent, thienopyridine, stroke, transient ischemic attack, thrombolysis
Abstract: Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Export Options
About this article
Cite this article as:
Biondi-Zoccai Giuseppe, Abbate Antonio, D’Ascenzo Fabrizio, Lotrionte Marzia and G. Modena Maria, Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812782
DOI https://dx.doi.org/10.2174/157016112800812782 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Role of Genetic Factors in Statins Side-Effects
Cardiovascular & Hematological Disorders-Drug Targets A Proteomic Analysis of the Virulence Factors of Three Common Bacterial Species Involved in Periodontitis and Consequent Possible Atherosclerosis: A Narrative Review
Current Protein & Peptide Science Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Current Clinical Pharmacology Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Central Nervous System Activities of Indole Derivatives: An Overview
Central Nervous System Agents in Medicinal Chemistry Protease Inhibitors with Antileishmanial Activity
Current Enzyme Inhibition Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry Alcohol Addiction: A Molecular Biology Perspective
Current Medicinal Chemistry Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Left Ventricular Hypertrophy: A Shift in Paradigm
Current Medicinal Chemistry